Ro-3306

Name: Ro-3306
Brand: Selleck Chemicals
SKU: S7747
Rating: 5 (64 reviews)

For research use only.

Catalog No.S7747

64 publications

CAS No. 872573-93-8

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.

Selleck's Ro-3306 has been cited by 64 publications

Nature, 2016, 539(7627):54-58

PubMed: 27760120 ( click the link to review the publication )

Mol Cell, 2021, S1097-2765(20)30951-5

PubMed: 33453166 ( click the link to review the publication )

Cell Res, 2020, 10.1038/s41422-020-0357-y

PubMed: 32561861 ( click the link to review the publication )

Mol Cell, 2020, 22 pii: S1097-2765(20)30231-8

PubMed: 32353258 ( click the link to review the publication )

Nat Commun, 2020, 11(1):4338

PubMed: 32859893 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1819

PubMed: 32286328 ( click the link to review the publication )

EMBO J, 2020, 2;e104036

PubMed: 32484965 ( click the link to review the publication )

Dev Cell, 2020, 55(6):707-722.e9

PubMed: 33321102 ( click the link to review the publication )

Genes Dev, 2020, 1;34(9-10):650-662

PubMed: 32217664 ( click the link to review the publication )

EMBO Rep, 2020, e48686

PubMed: 32484300 ( click the link to review the publication )

Cancer Res, 2020, 20 pii: canres 883 2019

PubMed: 32312836 ( click the link to review the publication )

Cell Rep, 2020, 32(11):108140

PubMed: 32937135 ( click the link to review the publication )

Cell Rep, 2020, 32(9):108080

PubMed: 32877684 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038/s41418-020-00641-7

PubMed: 33110216 ( click the link to review the publication )

Cancers (Basel), 2020, 24;12(4) pii: E1054

PubMed: 32344689 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):E1637

PubMed: 32575711 ( click the link to review the publication )

Cells, 2020,

PubMed: 32846968 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12882

PubMed: 33320980 ( click the link to review the publication )

Cell Discov, 2020, 28;6:26

PubMed: 32351706 ( click the link to review the publication )

Cell Transplant, 2020, 29:963689720950226

PubMed: 32841050 ( click the link to review the publication )

Gland Surg, 2020, 9(2):558-574

PubMed: 32420291 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):180

PubMed: 32152291 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(3)

PubMed: 32033461 ( click the link to review the publication )

J Cell Sci, 2020, 133(14):jcs243857

PubMed: 32591484 ( click the link to review the publication )
Neuroendocrinology, 2020, 10.1159/000509865

PubMed: 32615570 ( click the link to review the publication )

Viruses, 2020, 6;12(3):289

PubMed: 32155766 ( click the link to review the publication )

Development, 2020, 147(13):dev184838

PubMed: 32620578 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Mol Cell, 2019, 75(2):267-283

PubMed: 31202576 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2253

PubMed: 31138795 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz602

PubMed: 31291454 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1915108116

PubMed: 31712441 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(27):13374-13383

PubMed: 31209037 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31484670 ( click the link to review the publication )

Cell Rep, 2019, 26(4):955-968.e3

PubMed: 30673617 ( click the link to review the publication )

Elife, 2019, 8e44161

PubMed: 30860482 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

FASEB J, 2019, 33(4):5334-5349

PubMed: 30668924 ( click the link to review the publication )

J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Open Biol, 2019, 9(8):190136

PubMed: 31455158 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4511

PubMed: 30375385 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

FEBS Lett, 2018, 592(11):1893-1904

PubMed: 29782647 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30545129 ( click the link to review the publication )

Cancer research, 2018, 10.1158/0008-5472.CAN-17-2288

PubMed: ( click the link to review the publication )
FASEB J, 2018, 10.1096/fj.201801369R

PubMed: 30496702 ( click the link to review the publication )

Nat Commun, 2017, 8(1):2039

PubMed: 29229926 ( click the link to review the publication )

Elife, 2017, 6e30523

PubMed: 29106372 ( click the link to review the publication )

Oncogene, 2017, 36(44):6177-6189

PubMed: 28869606 ( click the link to review the publication )

EBioMedicine, 2017, 19:18-30

PubMed: 28434945 ( click the link to review the publication )

Sci Rep, 2017, 7:44464

PubMed: 28290553 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(20)

PubMed: 28760773 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )

Sci Rep, 2017, 7:41950

PubMed: 28176818 ( click the link to review the publication )

Nat Commun, 2016, 7:12880

PubMed: 27634057 ( click the link to review the publication )

Arthritis Rheumatol , 2016, 68(5):1222-32

PubMed: 26663909 ( click the link to review the publication )

Cell Cycle, 2016, 15(20):2742-52

PubMed: 27580187 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0149099

PubMed: 26881434 ( click the link to review the publication )

J Cell Biol, 2015, 209(2):221-34

PubMed: 25918224 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Targets

CDK1 ^[1] (Cell-free assay)	PKCδ ^[1] (Cell-free assay)	SGK ^[1] (Cell-free assay)	ERK ^[1] (Cell-free assay)
20 nM(Ki)	318 nM(Ki)	497 nM(Ki)	1980 nM(Ki)

In vitro

RO-3306 inhibits CDK1/cyclin B1, CDK1/cyclin A, CDK2/cyclin E, and CDK4/cyclin D activity with Ki of 35 nM, 110 nM, 340 nM, and over 2000 nM, respectively. Treatment of HCT116, SW480, and HeLa cells with RO-3306 for 20 h leads to a complete block of the cell cycle in the G2/M phase. The proliferation of both HCT116 and SW480 is effectively blocked by RO-3306. RO-3306 appears to be more proapoptotic in cancer cells (HCT116 and SW480) than nontumorigenic cells (MCF 10A and MCF 12A).^[1] RO-3306 effectively arrests oocyte maturation at a concentration of 10 μM.^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
KB-3-1 adenocarcinoma cell line	MXzxTHRUKGG\|c3H5		NGfFb5ZRNWeueXPvdJJwfGWrbjDzeYJ{fHKjdHXzJIll\W62aX\p[YQhcW5iS1KtN{0yKGGmZX7vZ4Fz[2mwb33hJINmdGxibHnu[UwheUiWUzD0bIVz[XCndYTpZ{BtcWK{YYL5JJNkemWnbh?=	NIfXOWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MUWxOVI5PCd-M{G1NVUzQDR:L3G+
human H460a cells	NXfxSphiWHKxbHnm[ZJifGmxbjDhd5NigQ>?		NXjlVXRNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIOFYx[SClZXzsd{whUUN3ME2xMlA1KM7:TR?=	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzNyM{SyNUc,OTd\|MEO0NlE9N2F-
human MDA435 cells	NHzBS4NRem:uaX\ldoF1cW:wIHHzd4F6		NXK4SmRQSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGE1OzViY3XscJMtKEmFNUC9NU4yPCEQvF2=	MlXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|MEO0NlEoRjF5M{CzOFIyRC:jPh?=
human HCT116 cells	MlnZVJJwdGmoZYLheIlwdiCjc4PhfS=>		MnTsRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOsJGlEPTB;MT6xOEDPxE1?	NHnH[3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OwN\|QzOSd-MUezNFM1OjF:L3G+
human RKO cells	NGCydlVRem:uaX\ldoF1cW:wIHHzd4F6		MVfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKNTzDj[YxteyxiSVO1NF0zKM7:TR?=	NYrCXoh3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUezNFM1OjFpPkG3N\|A{PDJzPD;hQi=>
human SW480 cells	M{HHNXBzd2yrZnXyZZRqd25iYYPzZZk>		MlzJRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVV{S4NEBk\WyuczygTWM2OD1{LkKg{txO	NH3MUIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{OwN\|QzOSd-MUezNFM1OjF:L3G+
human SJSA1 cells	Mlu1VJJwdGmoZYLheIlwdiCjc4PhfS=>		MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOMU1GxJINmdGy\|LDDJR\|UxRTRwNUWg{txO	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzNyM{SyNUc,OTd\|MEO0NlE9N2F-
human HCT116 cells	MoX2R5l1d3SxeHnjxsBie3OjeR?=	Mke3OUBl[Xm\|	MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgOUBl[Xm\|IHL5JG1VWyCjc4Phfg+9lCCLQ{WwQVMvOiEQvF2=	Mk\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|Mk[xOlgoRjJ{M{K2NVY5RC:jPh?=
NCI-SNU-1	M1e1N2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlziTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvU17VMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwN{OwPVUh\|ryPLh?=	MmjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
H4	NV3DNVZ3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYHJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzLkG1PFc2KM7:TT6=	NWX4UIZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
PA-1	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWXJcohq[mm2aX;uJI9nKGi3bXHuJHBCNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuNlI3PTRizszNMi=>	MmXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
T98G	NF\kRZFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4\jXmlvcGmkaYTpc44hd2ZiaIXtZY4hXDl6RzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU4{PjhzMjFOwG0v	NYHRSJpyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
SW1710	MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MnH0TY5pcWKrdHnvckBw\iCqdX3hckBUXzF5MUCgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvPjF2MEig{txONg>?	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
U251	NUHZbIpiT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWjJcohq[mm2aX;uJI9nKGi3bXHuJHUzPTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGuOlM4PzFizszNMi=>	M4niN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
ALL-PO	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Ml;sTY5pcWKrdHnvckBw\iCqdX3hckBCVExvUF:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEvQTB6MUOg{txONg>?	NEjVbpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SK-N-DZ	M33m[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX7jeYFMUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OMWRbKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{LkCxPFc3KM7:TT6=	M2C4eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
A4-Fuk	MorhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXrVOlE1UW6qaXLpeIlwdiCxZjDoeY1idiCDND3GeYsh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJwMEW2NFQh\|ryPLh?=	MnnJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
639-V	NXrRRmN3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4TNUWlvcGmkaYTpc44hd2ZiaIXtZY4hPjN7LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIvOjd3M{eg{txONg>?	NY\4PXBFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
Hs-578-T	NFPvUmVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIPNNWpKdmirYnn0bY9vKG:oIHj1cYFvKEi\|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{LkK3O\|k6KM7:TT6=	NETSNJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
UM-UC-3	MkfpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkX2TY5pcWKrdHnvckBw\iCqdX3hckBWVS2XQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzNjd\|OUO2JO69VS5?	NGL6WIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
BPH-1	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmDFTY5pcWKrdHnvckBw\iCqdX3hckBDWEhvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk46PzR3NTFOwG0v	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
5637	M1fnb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M4G5UmlvcGmkaYTpc44hd2ZiaIXtZY4hPTZ\|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN{4xQDV\|MjFOwG0v	M1HydVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
8-MG-BA	MlLaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NH;OUXlKdmirYnn0bY9vKG:oIHj1cYFvKDhvTVetRmEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwMUSwOFkh\|ryPLh?=	NFLrR5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
LB1047-RCC	NV7FbmNjT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVjJcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDNwMkO1NFEh\|ryPLh?=	NVSxR3NzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
KOSC-2	MoLoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVHJcohq[mm2aX;uJI9nKGi3bXHuJGtQW0NvMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN{41PDZ4MjFOwG0v	MoDSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
COR-L88	M2\McWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYXJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OOEigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMvPDd3OEOg{txONg>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
PSN1	Mk\sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NIXONotKdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvOTB6MEWg{txONg>?	NIfzNXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
LXF-289	NH;uS4JIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NIrOXGNKdmirYnn0bY9vKG:oIHj1cYFvKEy[Rj2yPFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwMkG3OkDPxE1w	M{f3[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
MN-60	M3\3e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUXJcohq[mm2aX;uJI9nKGi3bXHuJG1PNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0MlM4PjJ\|IN88UU4>	NFrLOnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NEC8	NXXaNVVoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NELnfoVKdmirYnn0bY9vKG:oIHj1cYFvKE6HQ{igZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQvPDdyN{[g{txONg>?	MlnDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H2405	M3Kze2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1jCT2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyOFA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Lke0OFk{KM7:TT6=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
YH-13	Mmj6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXfROmtOUW6qaXLpeIlwdiCxZjDoeY1idiC\SD2xN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPC55NUe3OkDPxE1w	NFHhRnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SK-MEL-2	NGLVT2hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MlPDTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPS5yOU[zNkDPxE1w	NWT6fld3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NB13	MV3Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUnJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEWuN\|I4QDZizszNMi=>	NEXRXm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
GAMG	M3m3cGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXP0XWhMUW6qaXLpeIlwdiCxZjDoeY1idiCJQV3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjN5MUWg{txONg>?	NH7kWmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NCI-H1792	NXPaT\|dzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWrJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUe5NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPS52N{m1OEDPxE1w	M1;NdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
KP-4	NYLGcY5HT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NU\VbHlGUW6qaXLpeIlwdiCxZjDoeY1idiCNUD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA2NjZ7OEKzJO69VS5?	Mk\wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
HGC-27	NGnRXYJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFLJbpVKdmirYnn0bY9vKG:oIHj1cYFvKEiJQz2yO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPS55M{C3O{DPxE1w	MmfZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
GCT	NGLwXZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYH6OJE1UW6qaXLpeIlwdiCxZjDoeY1idiCJQ2SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvQDVzMkGg{txONg>?	NF\zWWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
PFSK-1	NHvYOlVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NVywN5B[UW6qaXLpeIlwdiCxZjDoeY1idiCSRmPLMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDVwOE[xOlgh\|ryPLh?=	NHjORYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
A172	NF3yeYlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MXHJcohq[mm2aX;uJI9nKGi3bXHuJGEyPzJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEWuPVA4QSEQvF2u	NEnqcoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HO-1-N-1	M4XD[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2e4R2lvcGmkaYTpc44hd2ZiaIXtZY4hUE9vMT3OMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDVwOUW0NlUh\|ryPLh?=	M3G0c\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HN	NFTmR5VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUXJcohq[mm2aX;uJI9nKGi3bXHuJGhPKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB3Lkm3NFk4KM7:TT6=	NX\FOHZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
IST-MES1	NVywWnRYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWHwPVVVUW6qaXLpeIlwdiCxZjDoeY1idiCLU2StUWVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNT65O\|UzOSEQvF2u	M2jjdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
TGW	NWXmd21rT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVHwNVd[UW6qaXLpeIlwdiCxZjDoeY1idiCWR2egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFYvODV4OEKg{txONg>?	NIOxOZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
COR-L23	NX6zZYlHT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M4H1ZWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVyyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPi5\|N{O1JO69VS5?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
D-566MG	NU\n[5JYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVzJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTZ4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFYvPzh6N{Og{txONg>?	M{\ycVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
SKG-IIIa	Ml\xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NX7ZOYNVUW6qaXLpeIlwdiCxZjDoeY1idiCVS1etTWlK[SClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNj64OVU4OiEQvF2u	MnfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H446	NX\McZl5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NFzWVFJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOFQ3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB5LkCxPFEh\|ryPLh?=	M3vxRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
KYSE-270	NWHRWYQxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWjJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvMkewJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4NjB\|OEeyJO69VS5?	NF;2eXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
CAL-39	NXTSeVE4T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1X6ZWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUO5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4NjN3MkSg{txONg>?	M4\xSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
IST-SL1	NHLPRXlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXTnU3h7UW6qaXLpeIlwdiCxZjDoeY1idiCLU2StV2wyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB5LkSzN\|Q6KM7:TT6=	NUK3RZp7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
SF539	M3f0[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVK1TnVmUW6qaXLpeIlwdiCxZjDoeY1idiCVRkWzPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPy53NUG5O{DPxE1w	NYLTSIViRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
TE-1	NFP2OGtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX\5UopJUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA4Njh7MEmxJO69VS5?	M37qUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NB10	NV\Bc3F1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M2XNVmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gO{46QDd3ODFOwG0v	NGf3TVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
8505C	NEjV[pBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NX3iO2txUW6qaXLpeIlwdiCxZjDoeY1idiB6NUC1R{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPy57OUixO{DPxE1w	M{H2[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
DB	M4LRUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NEmybZpKdmirYnn0bY9vKG:oIHj1cYFvKESEIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC4MlAyOTNzIN88UU4>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H28	MonLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mo[2TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA5NjV7OEi0JO69VS5?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
LOXIMVI	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		Mn3KTY5pcWKrdHnvckBw\iCqdX3hckBNV1iLTW\JJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA5NjZ\|N{CxJO69VS5?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
ME-180	NFixSZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1TidWlvcGmkaYTpc44hd2ZiaIXtZY4hVUVvMUiwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA5NjhyM{m1JO69VS5?	MonEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
ES3	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4fmWWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC5MlEzPzl2IN88UU4>	NYDXe5JbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
SK-N-FI	M1PNbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{Hue2lvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3GTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hQS52MU[5PUDPxE1w	NX;5[HdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NBsusSR	Mn;sS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NX2zfJJEUW6qaXLpeIlwdiCxZjDoeY1idiCQQoP1d3NTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMD6yN\|E5KM7:TT6=	M3HZVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
GI-ME-N	MXPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NV3qbFIxUW6qaXLpeIlwdiCxZjDoeY1idiCJST3NSU1PKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMD6yO\|g{KM7:TT6=	MkTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
A704	MlHoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NEDDU3pKdmirYnn0bY9vKG:oIHj1cYFvKEF5MESgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFExNjN\|MUig{txONg>?	M{XzdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HuP-T4	NUTJV5lrT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWSzXpkxUW6qaXLpeIlwdiCxZjDoeY1idiCKdWCtWFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFyLkSyO\|Eh\|ryPLh?=	M4jK[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
A101D	M2jOVmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M1j2eWlvcGmkaYTpc44hd2ZiaIXtZY4hSTFyMVSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjF3N{Sg{txONg>?	MofiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
MCF7	MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NIfWSlJKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjF6NEmg{txONg>?	MlziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
A549	MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MYDJcohq[mm2aX;uJI9nKGi3bXHuJGE2PDliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGxMlIxPiEQvF2u	M2n2NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HD-MY-Z	Ml23S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NFXIZnNKdmirYnn0bY9vKG:oIHj1cYFvKEiGLV3ZMXoh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFzLkKwOkDPxE1w	NX3wT5VnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HCC1395	MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1HmdGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOFMUO5OUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTFwNUW5OkDPxE1w	Mn3IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	MkTlS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXyyRoxUUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3OSXAuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUGuO\|M{OiEQvF2u	MoHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
HSC-2	M4TnT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWfJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNU44QDR{IN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HCC1937	NGLmfGxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYDJcohq[mm2aX;uJI9nKGi3bXHuJGhESzF7M{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEyNjh2N{Og{txONg>?	NYKyS49nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
RS4-11	MmXNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYnBRppLUW6qaXLpeIlwdiCxZjDoeY1idiCUU{StNVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFzLki4N\|Yh\|ryPLh?=	Mo\tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
CAL-27	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYq0TIJGUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytNlch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{LkG2N\|ch\|ryPLh?=	NFnodmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NCI-H23	MknYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHrlSGNKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{LkSxOVUh\|ryPLh?=	M2\pNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
A431	NFf3SoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		Mke2TY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxNk44OjN\|IN88UU4>	M17OcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HT-1080	NVnOV2ZFT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NECwfpRKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF{LkezO\|Mh\|ryPLh?=	NVHodXpnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
GB-1	NH71UVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NI[5VXNKdmirYnn0bY9vKG:oIHj1cYFvKEeELUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFEzNjd5MU[g{txONg>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
BFTC-909	M4fiVGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkPrTY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTNwMUC2PEDPxE1w	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
CAL-33	MnmzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4DZW2lvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUOzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOy54NUG4JO69VS5?	MortQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
JVM-3	NVn0TnJ2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NULBN\|NSUW6qaXLpeIlwdiCxZjDoeY1idiCMVl2tN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTRwMk[yO{DPxE1w	M3\SW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
AN3-CA	NWTKNWYzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MUHJcohq[mm2aX;uJI9nKGi3bXHuJGFPOy2FQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVQvQTV5ODFOwG0v	MlXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
VM-CUB-1	M{fLdmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXrLO29NUW6qaXLpeIlwdiCxZjDoeY1idiCYTT3DWWIuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUWuNVM3PCEQvF2u	NVT5d5I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
A253	M2\P[Wdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NUi1dHBvUW6qaXLpeIlwdiCxZjDoeY1idiCDMkWzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPS5{OEO0JO69VS5?	NHjMe\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
RPMI-7951	NWjjRlBsT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYfhV21vUW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVc6PTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEG2MlE6QDFizszNMi=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H1563	MoW5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYjJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOTZwOEK1N{DPxE1w	NW\BOIJnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
LB831-BLC	NIHlVVhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2fTT2lvcGmkaYTpc44hd2ZiaIXtZY4hVEJ6M{GtRmxEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzNz6xPVI6KM7:TT6=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
ES8	NHLuVZBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2PzdGlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxO{4{OTV5IN88UU4>	NFrvOlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NCI-H292	NWnZRodMT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGfDZ2hKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlkzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzNz60O\|Q6KM7:TT6=	NI\Oc\|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
OAW-42	NUHrSFRnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MU\Jcohq[mm2aX;uJI9nKGi3bXHuJG9CXy12MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVcvQDh{MzFOwG0v	MkjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
RCC10RGB	MlTiS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4DjS2lvcGmkaYTpc44hd2ZiaIXtZY4hWkOFMUDSS2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDF5Lkm1O\|gh\|ryPLh?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
PC-3	NH2xcmtIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M1Xpd2lvcGmkaYTpc44hd2ZiaIXtZY4hWENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVgvODB2MzFOwG0v	NHvadJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HCC38	NXWxcVlXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MXfJcohq[mm2aX;uJI9nKGi3bXHuJGhESzN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxPE4yODNzIN88UU4>	M1TybVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
DEL	Ml7WS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHq0cVhKdmirYnn0bY9vKG:oIHj1cYFvKESHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVgvOzh5IN88UU4>	NWTQPYZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
ABC-1	NU\5c\|BuT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3HuN2lvcGmkaYTpc44hd2ZiaIXtZY4hSUKFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE5NjV4Mkeg{txONg>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SW756	M1TzUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MYLJcohq[mm2aX;uJI9nKGi3bXHuJHNYPzV4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxPU4yOzVzIN88UU4>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
TE-6	NYnDTlF1T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGnlWZpKdmirYnn0bY9vKG:oIHj1cYFvKFSHLU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE6NjJzMEOg{txONg>?	NGHtfIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
H-EMC-SS	M3TBeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXS2[lB[UW6qaXLpeIlwdiCxZjDoeY1idiCKLVXNR{1UWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUmuOFM2QSEQvF2u	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HCT-116	NV;iZ5pQT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NUC5d\|VsUW6qaXLpeIlwdiCxZjDoeY1idiCKQ2StNVE3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzOT62Olgh\|ryPLh?=	NV;WPYNlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
CHP-212	NFrjVXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MoPBTY5pcWKrdHnvckBw\iCqdX3hckBEUFBvMkGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQS55NEe4JO69VS5?	NGnsfIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SK-LU-1	MoXNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mk\6TY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyQS55NUOg{txONg>?	NWLRW3lDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HT-3	MnTtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVrmSnI4UW6qaXLpeIlwdiCxZjDoeY1idiCKVD2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOC5yMkig{txONg>?	MlTzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
KG-1	MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4jzRWlvcGmkaYTpc44hd2ZiaIXtZY4hU0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlAvOjB4IN88UU4>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
ES1	MoPuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MWHJcohq[mm2aX;uJI9nKGi3bXHuJGVUOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkGuNFA1QCEQvF2u	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	NWLUXGtPT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NW\ScZp1UW6qaXLpeIlwdiCxZjDoeY1idiCUYX3vd{0zTzZvNFOxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjFwN{e1OkDPxE1w	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
IA-LM	NHvGVZVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWDkNZZ7UW6qaXLpeIlwdiCxZjDoeY1idiCLQT3MUUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjFwOU[5OEDPxE1w	NE\3PFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
BHT-101	MnzxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{Kwe2lvcGmkaYTpc44hd2ZiaIXtZY4hSkiWLUGwNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjJwME[yPUDPxE1w	MknqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
OVCAR-4	MlLjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NVrvbJpIUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Mj60O{DPxE1w	NV:zeZJIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
SW1573	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MmXYTY5pcWKrdHnvckBw\iCqdX3hckBUXzF3N{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIzNjd7M{Sg{txONg>?	NUfqdJRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
CHL-1	NV\pRlRIT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWrJcohq[mm2aX;uJI9nKGi3bXHuJGNJVC1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyN{4zQDN\|IN88UU4>	M3;teFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
BFTC-905	M3rVfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlnkTY5pcWKrdHnvckBw\iCqdX3hckBDTlSFLUmwOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjNwMki5NkDPxE1w	NGf6bZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
TE-12	MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlflTY5pcWKrdHnvckBw\iCqdX3hckBVTS1zMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlMvPTd6MjFOwG0v	NUXNdlZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NCI-H358	NYP3coJoT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoHFTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEO1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjNwNkS3O{DPxE1w	M4jIU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
OVCAR-5	M4rDbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NH;IToFKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ2LkGwOEDPxE1w	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
CGTH-W-1	M4PJU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXzJcohq[mm2aX;uJI9nKGi3bXHuJGNIXEhvVz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPS5yOEC0JO69VS5?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
SNU-423	M1joU2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NX7Ud\|g4UW6qaXLpeIlwdiCxZjDoeY1idiCVTmWtOFI{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{NT6zOlYh\|ryPLh?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
CP50-MEL-B	NV7tPYNCT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NGDu[m1KdmirYnn0bY9vKG:oIHj1cYFvKEOSNUCtUWVNNUJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK1Mlc{QTlizszNMi=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H2087	M365PGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHPU[HZKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA5PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkWuPFY2PSEQvF2u	M1vK[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
RMG-I	NILZdZlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmrCTY5pcWKrdHnvckBw\iCqdX3hckBTVUdvSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlUvQTJzOTFOwG0v	NGKxTmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
KP-N-YS	MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlX1TY5pcWKrdHnvckBw\iCqdX3hckBMWC2QLWnTJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPi5{MEKg{txONg>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
OMC-1	NHG4bldIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MmryTY5pcWKrdHnvckBw\iCqdX3hckBQVUNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlYvPTB6IN88UU4>	NH\mZpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
DMS-114	MnPoS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHi4WJZKdmirYnn0bY9vKG:oIHj1cYFvKESPUz2xNVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ5LkO5OlYh\|ryPLh?=	NI\2fHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SHP-77	Mom3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHzpPWNKdmirYnn0bY9vKG:oIHj1cYFvKFOKUD23O{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjdwNEi4JO69VS5?	NYC1cHUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
MPP-89	NGjBT45Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2\ofmlvcGmkaYTpc44hd2ZiaIXtZY4hVVCSLUi5JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPy57NEO4JO69VS5?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H1581	NFXuWldIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NV[xNmM6UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFE2QDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK4MlQ2OzVizszNMi=>	NIqwbmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
D-283MED	MmXNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Mn\VTY5pcWKrdHnvckBw\iCqdX3hckBFNTJ6M13FSEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjhwNE[3OEDPxE1w	NW\aU2t3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
MOLT-4	NH\5VGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M3TyNWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzQC57MEeyJO69VS5?	M3H6VVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
ES6	NVXHO29HT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M1PrNWlvcGmkaYTpc44hd2ZiaIXtZY4hTVN4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyPU43PDN4IN88UU4>	NHTBUmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NB6	NXHFd\|RZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVrF[m91UW6qaXLpeIlwdiCxZjDoeY1idiCQQk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI6Njh4M{ig{txONg>?	MoPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SW954	Mnr4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHfoVWJKdmirYnn0bY9vKG:oIHj1cYFvKFOZOUW0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzQS57NEC3JO69VS5?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
A388	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGE{QDhiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK5Mlk1OjJizszNMi=>	MnXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
OAW-28	NFjDV49Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVPJcohq[mm2aX;uJI9nKGi3bXHuJG9CXy1{ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|AvOjJ5ODFOwG0v	MkjsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SK-MES-1	M4[2bmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGHjcFlKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FV{0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|MT6yNlA5KM7:TT6=	NELjTYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NCI-H441	M{\UOWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MUfJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNESxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS57OE[4JO69VS5?	NU[3ZoVqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HOP-92	NVu3W3FyT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWfJcohq[mm2aX;uJI9nKGi3bXHuJGhQWC17MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|IvOjN3NjFOwG0v	NVixb4g{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
NB14	MWfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXvJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOyMlczPTFizszNMi=>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
MS-1	MnHES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MXfJcohq[mm2aX;uJI9nKGi3bXHuJG1UNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEOyMlc3ODRizszNMi=>	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
YKG-1	NFr4WolIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkPWTY5pcWKrdHnvckBw\iCqdX3hckB[U0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|IvQDN\|NjFOwG0v	NFrqXpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
SiHa	NXnFNWtnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MkfITY5pcWKrdHnvckBw\iCqdX3hckBUcUijIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzN{4{QDJ7IN88UU4>	NX\nUXZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HAL-01	MVXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1zjNWlvcGmkaYTpc44hd2ZiaIXtZY4hUEGOLUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PC5{M{e2JO69VS5?	M4fOOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
Ca-Ski	MkTPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUHJcohq[mm2aX;uJI9nKGi3bXHuJGNiNVOtaTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|QvPzZ4OTFOwG0v	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H747	NIKzVVJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MUPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{S3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PC57OEe1JO69VS5?	NFrRVJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
KYSE-510	NI\xdGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MWPJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PS54NEi1JO69VS5?	NWXqeFd7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
A204	M4j6dmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3nUcmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|UvPzJyOTFOwG0v	M4raTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HSC-3	M{LsUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGjC[\|BKdmirYnn0bY9vKG:oIHj1cYFvKEiVQz2zJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Pi5yMEi2JO69VS5?	NFvkW289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HuP-T3	M1PkWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVPWeJN5UW6qaXLpeIlwdiCxZjDoeY1idiCKdWCtWFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN4LkS4N\|Ih\|ryPLh?=	MmXNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
RPMI-8226	M4fyZWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXW4XVR7UW6qaXLpeIlwdiCxZjDoeY1idiCUUF3JMVgzOjZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEO2MlYzODhizszNMi=>	MoGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	MkLZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkXoTY5pcWKrdHnvckBw\iCqdX3hckBSUU2ULWfJUEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzZwNkS0JO69VS5?	NVjLSHJ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
HuH-7	M{D4W2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3ThcGlvcGmkaYTpc44hd2ZiaIXtZY4hUHWKLUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM5NjZzOESg{txONg>?	MlO5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
CAL-12T	NYn6b5NET3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M{HkXWlvcGmkaYTpc44hd2ZiaIXtZY4hS0GOLUGyWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzhwOUSxOkDPxE1w	MkHrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
GT3TKB	NVHMc2hnT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NVPxNXB5UW6qaXLpeIlwdiCxZjDoeY1idiCJVEPUT2Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN7LkG5NlEh\|ryPLh?=	M1vENVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
OC-314	MlzxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MUDJcohq[mm2aX;uJI9nKGi3bXHuJG9ENTNzNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|kvPzF{NTFOwG0v	NHOyOFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NCI-H2228	MnzMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NI\1c\|NKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlIzQCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNECuNVQxOyEQvF2u	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
NCI-H727	M2\JTGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MXPJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{K3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OC5{NUOxJO69VS5?	NH;lSpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	NHjWR\|VIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXyySJNCUW6qaXLpeIlwdiCxZjDoeY1idiCQVFXSRU1UNWOuLVSxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OC52N{C2JO69VS5?	M4m4RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
MMAC-SF	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M{DETGlvcGmkaYTpc44hd2ZiaIXtZY4hVU2DQz3TSkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDBwOUKzOUDPxE1w	NHq2bYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
HTC-C3	NIK1coxIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NULJPY5HUW6qaXLpeIlwdiCxZjDoeY1idiCKVFOtR\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRzLkSxOlkh\|ryPLh?=	M2POTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
SF295	MmLRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MkLqTY5pcWKrdHnvckBw\iCqdX3hckBUTjJ7NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFEvPTN5OTFOwG0v	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
U-2-OS	NXfj[I5[T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MX7Jcohq[mm2aX;uJI9nKGi3bXHuJHUuOi2RUzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFEvQDV4NzFOwG0v	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
HPAF-II	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXHJcohq[mm2aX;uJI9nKGi3bXHuJGhRSUZvSVmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQyNjl\|OEKg{txONg>?	NHu2eJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
KYSE-450	MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MWHJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNEWwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Oi52N{C3JO69VS5?	MoP1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
DMS-273	MkDhS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NWrTbJBNUW6qaXLpeIlwdiCxZjDoeY1idiCGTWOtNlc{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Mz6yPFM3KM7:TT6=	M1rqblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HT-1376	MlrQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Ml\vTY5pcWKrdHnvckBw\iCqdX3hckBJXC1zM{e2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Oy5\|MUW2JO69VS5?	MmWzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
786-0	MkHYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnfXTY5pcWKrdHnvckBw\iCqdX3hckA4QDZvMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFMvPjJ4MTFOwG0v	NIfNTpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
NCI-H810	Ml7uS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYXUWHF4UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFgyOCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNESuNFE{PiEQvF2u	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
8305C	MkC3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NXHBPZZXUW6qaXLpeIlwdiCxZjDoeY1idiB6M{C1R{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDRwNkS1JO69VS5?	Mof6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
DSH1	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWfpTIdQUW6qaXLpeIlwdiCxZjDoeY1idiCGU1ixJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1PS55MESyJO69VS5?	NUD3N2ZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
KYSE-520	M{PYbmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MoXTTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWyNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDZwNUeyNUDPxE1w	M4[2eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
TYK-nu	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFXEeFlKdmirYnn0bY9vKG:oIHj1cYFvKFS\Sz3ueUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDZwN{C5NkDPxE1w	MoXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
EPLC-272H	M4DrcGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MnLKTY5pcWKrdHnvckBw\iCqdX3hckBGWEyFLUK3Nmgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR4LkeyPFMh\|ryPLh?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
T-24	M3LzdGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NULsSHlOUW6qaXLpeIlwdiCxZjDoeY1idiCWLUK0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Py57MkmyJO69VS5?	NEL2e3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
BHY	M2TEc2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlewTY5pcWKrdHnvckBw\iCqdX3hckBDUFliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES3Mlk6QSEQvF2u	MnvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
NCI-H82	M2L5fGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M17re2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi4NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDhwMkG3JO69VS5?	MnvQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
SF268	M4PtNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml64TY5pcWKrdHnvckBw\iCqdX3hckBUTjJ4ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFgvPjF6OTFOwG0v	MormQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|k{QTJ7Lze+V2FPT0WUPD;hQi=>
C-33-A	MXLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUTJcohq[mm2aX;uJI9nKGi3bXHuJGMuOzNvQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFgvPzV3NDFOwG0v	NXjBPHJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
MIA-PaCa-2	NVnXfIE{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWfCV457UW6qaXLpeIlwdiCxZjDoeY1idiCPSVGtVIFE[S1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0PE45Ozh6IN88UU4>	M33GRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
HCC1954	NUL2VWIxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NF3QeWxKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G5OVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR7LkC4O\|Eh\|ryPLh?=	M1PFO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
NCI-H1666	MnHxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NHvaWXBKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVY3PiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNEmuN\|Y1OiEQvF2u	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzPVM6OjlxJ{7TRW5ITVJ:L3G+
GR-ST	M4TZ[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3z0emlvcGmkaYTpc44hd2ZiaIXtZY4hT1JvU2SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ6NjN4OUWg{txONg>?	M2D1RVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
Ca9-22	MkXTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnXDTY5pcWKrdHnvckBw\iCqdX3hckBE[TlvMkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ6NjRyMUOg{txONg>?	M37tfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFM6Ozl{OT:nQnNCVkeHUkyvZV4>
D-502MG	M4HjeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MWPJcohq[mm2aX;uJI9nKGi3bXHuJGQuPTB{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ6NjRzNzFOwG0v	NY\qWGx{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?
SCC-4	M1zSeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MlrPTY5pcWKrdHnvckBw\iCqdX3hckBUS0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFkvPTZyMjFOwG0v	NIDvXY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{QTN7MkmvK\|5USU6JRWK8M4E,
RKO	MmDmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NILuVo1KdmirYnn0bY9vKG:oIHj1cYFvKFKNTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFkvQDN3NjFOwG0v	NUnqXJdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzl\|OUK5M{c,W0GQR1XSQE9iRg>?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Cdk1 / Cdk1 / Cleaved PARP / Cleaved caspase-3 / p-p38 / Bad / Apaf1-1 / p-H2Ax / Bim / Bad; PubMed: 27385216 Oncotarget OVCA-429 and OVCAR-3 were exposed to RO-3306 for 24 h in indicated dose dependent manner, (F) 10 uM RO-3306 for 12 h up to 48 h. The expression level of the indicated protein and the phosphorylated form of H2A.x and p38 were examined via Western blot analyses.	27385216
Immunofluorescence	PARP1 / Plk1 ; PubMed: 28069876 Mol Cancer Ther Representative images of IF staining for PARP1 and Plk1 in 22RV1 cells treated with 0.3 mM mimosine for 20 h, 4 mM hydroxyurea for 24 h, 10 µM RO-3306 for 7 h or 200 ng/ml nocodazole (Noc) for 12 h.	28069876
Growth inhibition assay	Cell viability; PubMed: 27385216 Oncotarget OVCA-429 and OVCAR-3 were exposed to RO-3306 in indicated time- and dose-dependent manner. Cell viability were measured via crystal violet assay. Results are the means ± S.E. n = 3.	27385216

Protocol

Kinase Assay:^[1]

- Collapse

CDK assay:

The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.

Cell Research:^[3]

- Collapse

Cell lines: MDA-MB-231 cell line
Concentrations: 20 μM
Incubation Time: 72 h
Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	13 mg/mL warmed (36.98 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ro-3306 SDF

Molecular Weight	351.45
Formula	C₁₈H₁₃N₃OS₂
CAS No.	872573-93-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1=CC2=C(C=CC(=C2)C=C3C(=O)NC(=NCC4=CC=CS4)S3)N=C1

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
AT7519 HCl ^New

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol HCl

Flavopiridol HCl (NSC 649890 HCl, alvocidib, L86-8275, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Roscovitine (Seliciclib)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
Abemaciclib mesylate (LY2835219)

Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306